Who are Integrase Inhibitor's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Atripla (r), Doravirine, Tenofovir, Lamivudine, Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir, Cabotegravir OLI, Dolutegravir/Lamivudine as a single pill, Switch to DTG + 3TC.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/integrase-inhibitor.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Integrase Inhibitor — Competitive Intelligence Brief

Integrase Inhibitor (Integrase Inhibitor) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Integrase inhibitor. Area: Infectious Disease.

marketed Integrase inhibitor HIV integrase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Integrase Inhibitor (Integrase Inhibitor) — McGill University Health Centre/Research Institute of the McGill University Health Centre. Integrase inhibitors block HIV integrase, preventing the virus from inserting its genetic material into the host cell's DNA.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Integrase Inhibitor TARGET	Integrase Inhibitor	McGill University Health Centre/Research Institute of the McGill University Health Centre	marketed	Integrase inhibitor	HIV integrase
Atripla (r)	Atripla (r)	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Antiretroviral combination (NNRTI + NRTI + NtRTI)	HIV reverse transcriptase, HIV integrase
Doravirine, Tenofovir, Lamivudine	Doravirine, Tenofovir, Lamivudine	Merck Sharp & Dohme LLC	marketed	Antiretroviral combination (NNRTI + NRTIs)	HIV reverse transcriptase, HIV integrase
Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir	Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir	St Stephens Aids Trust	marketed	Antiretroviral agents (INSTI, NNRTI, NRTI/NtRTI)	HIV integrase (dolutegravir); HIV reverse transcriptase (efavirenz and combination); HIV entry (tenofovir/emtricitabine component)
Cabotegravir OLI	Cabotegravir OLI	ViiV Healthcare	marketed	Integrase strand transfer inhibitor (INSTI)	HIV integrase
Dolutegravir/Lamivudine as a single pill	Dolutegravir/Lamivudine as a single pill	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase; HIV reverse transcriptase
Switch to DTG + 3TC	Switch to DTG + 3TC	Hospitales Universitarios Virgen del Rocío	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase; HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Integrase inhibitor class)

McGill University Health Centre/Research Institute of the McGill University Health Centre · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Integrase Inhibitor — Competitive Intelligence Brief. https://druglandscape.com/ci/integrase-inhibitor. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab